Overview


According to FutureWise analysis the market for Patient Derived Xenograft Models in 2023 is US$ 0.28 billion, and is expected to reach US$ 0.75 billion by 2031 at a CAGR of 13.00%.

In order to study tumour biology, medication sensitivity, and drug tolerance, the patient-derived xenograft (PDX) paradigm entails transplanting human cancer tissues into immunodeficient mice. Compared to conventional cell line models, the PDX model offers a more therapeutically applicable and predictive model for cancer study. Xenograft tumour models are intended to maintain the original tumor's properties, including diverse morphology, malignant phenotypes, clinical biomolecular signature and genotype, tumour archive, and tumour vasculature at low passage. According to the widely held belief, xenographs created from patient samples can offer pertinent clinical information for assessing the efficacy of innovative cancer treatments.

Certain genes in tumours may be maintained by serial cancer transfer between mice. These models are commonly used in clinical trials, drug development, and tailored cancer treatment because they allow researchers studying the biology and pharmacology of tumours to perform in vitro cell culture tests without the need for human handling. When compared to genetically modified animals and cell line-derived xenograft models, PDX models have higher prognostic values for therapeutic outcomes. In one study, PDX models of colorectal cancer accurately predicted the response of patients to chemotherapy and targeted therapies, whereas traditional cell culture models did not. This suggests that PDX models may be a more reliable preclinical tool for evaluating the efficacy of new cancer therapies.

FutureWise Market Research has published a report that provides an insightful analysis of Patient Derived Xenograft Models Market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry. By the end of the forecast period FutureWise research analysts projects that Patient Derived Xenograft Models Market will experience a significant growth.

According to the analysis done, this report will help understand the information referring to the total valuation held by this industry. Additionally, this report will help in understanding the growth opportunities held by various segments of this market, further assist in making better strategic and expansion decisions by key stakeholders of an organization.
  • Crown Bioscience Inc.
  • WuXi AppTec 
  • Champions Oncology, Inc.
  • The Jackson Laboratory
  • ONCODESIGN
  • Charles River Laboratories International, Inc.
  • EPO Berlin-Buch GmBH
  • Shanghai LIDE Biotech Co., Ltd.
  • Xentech
  • Horizon Discovery Group PLC
  • JSR Corporation
  • Envigo
  • Pharmatest Services
  • Hera Biolabs 
  • Urosphere

(Note: The list of the major players will be updated with the latest market scenario and trends)

Recent developments by key players in Patient Derived Xenograft Models Market:

  • The research group of Professor Kamimura at Niigata University used the pancreas-targeted selective hydrodynamic gene delivery approach to develop a novel pancreatic cancer model in wild-type rats in April 2022.

The rising incidence of cancer is one of the major factors influencing the PDX industry. The World Health Organization says that cancer was the main causes of mortality globally in 2020, accounting for 10 million fatalities. To discover novel cancer medicines, there is an increasing demand for improved preclinical models as the prevalence of cancer keeps rising.

The rising need for customised medicine is another element influencing the PDX industry. With the use of PDX models, scientists may examine the distinctive traits of individual tumours and create tailored treatments based on the unique genetic profile of a patient. PDX models are a crucial tool in drug discovery as a result of the emergence of precision medicine. In addition, there is now more interest in PDX models due to the shortcomings of conventional preclinical models such as cell lines and mouse models. PDX models, which are created directly from patient tumours as opposed to conventional models, offer a more precise portrayal of the patient's condition and response to treatment. But, the PDX market is also dealing with difficulties. The expense and difficulty involved in creating and maintaining PDX models is one of the major concerns. Specialized facilities, techniques, and expertise is required for PDX models, and establishing them can be costly and time-consuming.

By Type           

  • Mice Models
  • Rat Models

By Tumor Type

  • Gastrointestinal Tumor Models (colorectal, pancreatic, hepatic, and cholangio tumors)
  • Gynecological Tumor Models (breast, ovarian, and cervical tumors)
  • Respiratory Tumor Models (lung tumors, nasopharyngeal, and bronchial tumors)
  • Urological Tumor Models (renal, prostate, and bladder tumors)
  • Hematological Tumor Models (leukemia and lymphoma)
  • Other Tumor Models (head & neck cancer, sarcoma, and melanoma)

By Application

  • Pre-clinical Drug Development and Basic Cancer Research
  • Biomarker Analysis

By End User

  • Pharmaceutical & Biotechnology Companies
  • Contract Research Organizations
  • Academic & Research Institutions

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  •  Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Over the course of the projection period, North America is anticipated to dominate the market for patient-derived xenograft models. The rise in cancer cases, growing public and private sector spending, and the existence of significant stakeholders in the region are all contributing elements. Based on end-user, contract research organization is expected to be the highest growing segment over the forecast period of 2023-2031 in the global market.
  • Tier 1 players- established companies in the market with major market share
  • Tier 2 players
  • New Entrants
  • growing rapidly
  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data points affecting market growth
  • To provide with an exhaustive analysis on the of Patient Derived Xenograft Models Market By Type, By Tumor Type, By Application, By End-User and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

 
  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Patient Derived Xenograft Models Market Variables, Trends and Scope

    •        1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Patient Derived Xenograft Models Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Patient Derived Xenograft Models Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Patient Derived Xenograft Models Market, By Type Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Mice Models
        2. Rat Models

  • 8.   Patient Derived Xenograft Models Market, By Tumor Type Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Gastrointestinal Tumor Models (colorectal, pancreatic, hepatic, and cholangio tumors)
        2. Gynecological Tumor Models (breast, ovarian, and cervical tumors)
        3. Respiratory Tumor Models (lung tumors, nasopharyngeal, and bronchial tumors)
        4. Urological Tumor Models (renal, prostate, and bladder tumors)
        5. Hematological Tumor Models (leukemia and lymphoma)
        6. Other Tumor Models (head and neck cancer, sarcoma, and melanoma)

  • 9.   Patient Derived Xenograft Models Market, By Application Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Pre-clinical Drug Development and Basic Cancer Research
        2. Biomarker Analysis

  • 10.   Patient Derived Xenograft Models Market, By End User Historical Analysis and Forecast 2023-2031 (USD Million)

    •   1. Pharmaceutical and Biotechnology Companies
        2. Contract Research Organizations
        3. Academic and Research Institutions

  • 11.   North America Patient Derived Xenograft Models Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 12.   Latin America Patient Derived Xenograft Models Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 13.   Europe Patient Derived Xenograft Models Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 14.   Asia Pacific Patient Derived Xenograft Models Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 15.   Middle East and Africa Patient Derived Xenograft Models Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)

    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 16.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 17.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)

    •       1. Crown Bioscience Inc.
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. WuXi AppTec
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Champions Oncology, Inc.
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. The Jackson Laboratory
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. ONCODESIGN
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Charles River Laboratories International, Inc.
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. EPO Berlin-Buch GmBH
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Shanghai LIDE Biotech Co., Ltd.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Xentech
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Horizon Discovery Group PLC
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview
        11. JSR Corporation
         11.1. Company Overview
         11.2. Product Portfolio
         11.3. SWOT Analysis
         11.4. Financial Overview
         11.5. Strategic Overview
        12. Envigo
         12.1. Company Overview
         12.2. Product Portfolio
         12.3. SWOT Analysis
         12.4. Financial Overview
         12.5. Strategic Overview
        13. Pharmatest Services
         13.1. Company Overview
         13.2. Product Portfolio
         13.3. SWOT Analysis
         13.4. Financial Overview
         13.5. Strategic Overview
        14. Hera Biolabs
         14.1. Company Overview
         14.2. Product Portfolio
         14.3. SWOT Analysis
         14.4. Financial Overview
         14.5. Strategic Overview
        15. Urosphere
         15.1. Company Overview
         15.2. Product Portfolio
         15.3. SWOT Analysis
         15.4. Financial Overview
         15.5. Strategic Overview

  • 18.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the healthcare regulations initiated by administrations
        5. The overall economic slowdown of the developing and developed nations
  • 19.   FutureWise SME Key Takeaway Points for Client

Ask for Discount
Buy Now
Customize This Report
  • We Offer Special Discounts for start-ups, NGOs, and Educational & Research institutions.

Need Assistance

  • UK : +44 141 628 9353
  • US : +1 347 709 4931

What you get

  • Excel Dataset
  • Market Overview
  • Infographics
  • PowerPoint Presentation
  • PDF Report

What's included

  • Consumer Perception and Procurement
  • Market Data Forecast
  • Competitive Analysis
  • Risks and Opportunity Assessment
  • Market Trends and Dynamics
Partner

Our Clients

image0
image1
image2
image3
image4
image5
image6
image7
image8
image9
image10
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11
image11